Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sosei Group ( (JP:4565) ) has provided an update.
Nxera Pharma reported a year of disciplined execution in 2025, strengthening its commercial base in Japan and APAC as PIVLAZ consolidated its position as standard of care in aneurysmal subarachnoid haemorrhage and delivered 6.8% annual sales growth. QUVIVIQ sales surged more than threefold following its December 2024 launch with Shionogi, supported by approval of an additional Asian manufacturing site to secure supply and improve profitability.
The company advanced its pipeline through partner-led milestones, including Neurocrine’s Phase 3 start for muscarinic agonist NBI-‘568 and positive Phase 1 data for oncology candidate HTL’732, which has moved into Phase 2. Nxera also executed a focused restructuring to prioritize high-value programs and cut costs toward a 2030 profitability target, regained full rights to its Phase 2–ready GPR52 schizophrenia asset for out-licensing, expanded its late-stage portfolio via licensing DMD drug vamorolone for Japan/APAC, and reported positive Phase 3 data for daridorexant in South Korea ahead of a 2026 filing.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma Co., Ltd., listed on the Tokyo Stock Exchange, is a biopharmaceutical company focused on developing and commercializing innovative medicines in Japan and the broader Asia-Pacific region. Its portfolio includes PIVLAZ for prevention of cerebral vasospasm after aneurysmal subarachnoid haemorrhage, QUVIVIQ for insomnia, and a growing pipeline in neuroscience, oncology, obesity and metabolic diseases, supported by partnerships with global pharma and research organizations.
Average Trading Volume: 875,488
Technical Sentiment Signal: Sell
Current Market Cap: Yen80.36B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.